Compare Enveric Biosciences Inc (ENVB) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tripadvisor Inc Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: Tripadvisor Inc Common Stock is far larger — about 151× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 3,004,748). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| ENVB | TRIP | |
|---|---|---|
Market Cap | $6.69M | $1.01B |
Volume | 41,141 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $16.72 |
52-Week Low | $1.27 | $8.04 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.60M | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TripAdvisor (TRIP) trades at $8.96, up 5.16% on the day but near its 52-week low of $8.27. The stock is technically bearish with recent earnings misses and a net cash outflow trend. Revenue grew to $1.89B in 2025 with a net income margin of 2.11%, but profitability remains volatile. Analyst consensus is a 'Hold' with a $13.58 price target, indicating cautious optimism amid competitive pressures from AI-driven travel platforms.
The outlook is mixed: valuation ratios like P/S of 0.57 suggest potential undervaluation, but persistent earnings misses and declining cash flow pose risks. Upside depends on stabilizing core offerings and successful subsidiary sales, while competition and search-related pressures threaten growth. Investors should weigh low valuation against execution challenges in a dynamic travel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
